Tenzing Acquisition Corp. in its latest filing set a shareholder vote for Dec. 8 on the proposed merger with Reviva, a California-based clinical stage pharmaceutical company. If approved, the merger would give the combined companies a valuation of $119M. Read more.
Related Posts
Neo Technology Acquisition Files for $40M IPO
The SPAC did not cite any specific sectors it might target, referring only to companies in North America and Asia.
Class Acceleration Prices $225M IPO
The new SPAC plans to target companies in education technology.
TortoiseEcofin III Files Investor Presentation on $300M One Energy Deal
The deal with the vertically integrated industrial power solutions company was announced in August at an implied pre-money enterprise value of $300 million.
Ventoux CCM Again Postpones Presto Deal Vote
A vote on the merger was originally set for June, but postponed as the SPAC raised $100 million in additional funding for the deal.